.jpg)
Wound-healing patches can vary in size and present indentations housing cytokine-secreting cells (right). In preclinical studies, delivery of cytokines using the patch supported accelerated wound healing.
Photo Credit: Jared Jones/Rice University
Scientific Frontline: Extended "At a Glance" Summary: Living Bandage (Cytokine Factory Patch)
The Core Concept: The living bandage is a cell-based delivery platform that utilizes encapsulated, engineered cells as on-site "factories" to secrete therapeutic signaling proteins directly into a wound over extended periods. It is designed to maintain therapeutic levels of tissue-regenerating molecules precisely where they are needed most.
Key Distinction/Mechanism: Unlike conventional cytokine delivery approaches that are limited by rapid degradation and poor retention at the wound site, this system provides sustained, localized immunomodulation. Engineered ARPE-19 cells are housed within a biocompatible hydrogel matrix that allows nutrients to enter and therapeutic proteins to exit, all while shielding the active cells from the host's immune system.
Major Frameworks/Components:
- Engineered ARPE-19 Cells: Cells genetically modified to continuously secrete specific healing cytokines, including IL-10, IL-12, and TGF-β.
- Biocompatible Hydrogel Matrix: A protective casing that isolates the therapeutic cells from the host immune system while remaining permeable to nutrients and secreted proteins.
- Transcriptomic Validation: The activation of key wound-healing pathways and upregulation of tissue regeneration genes were validated through RNA sequencing.
- Modular Platform: The system can be adapted to produce different combinations of growth factors or integrated with bioelectronic components for specific clinical applications.
Branch of Science: Bioengineering, Regenerative Medicine, Immunology, and Synthetic Biology.
Future Application: The platform's modularity opens the door to real-time, optogenetic control of cytokine secretion. Beyond wound care, the technology provides a foundational framework for localized, cell-based therapeutic protein delivery across various diseases requiring sustained, site-specific cell signaling.
Why It Matters: Chronic wounds present a massive clinical challenge due to the difficulty of coordinating tissue repair. By continuously engaging the body's natural immune response directly at the injury site, the living bandage significantly accelerates natural repair processes and healing outcomes.
.jpg) |
| Christian Schreib and Elizabeth Kelley Photo Credit: Jared Jones/Rice University |
Chronic wounds remain a significant clinical challenge, in part because it is difficult to deliver sustained, localized immune signals that coordinate tissue repair. While cytokines play a central role in regulating inflammation and healing, conventional delivery approaches are often limited by rapid degradation and poor retention at the wound site.
Researchers at Rice University, with the support of the Rice Biotech Launch Pad, have developed a cytokine factory patch designed to address this challenge by continuously producing and delivering therapeutic cytokines directly within the wound environment. The approach is described in a new peer-reviewed study, titled “Cytokine Factory Patch for Localized Immunomodulation to Accelerate Healing in Rodent and Porcine Excisional Wound Models,” published in Nature Biomedical Engineering.
The cytokine factory patch is a cell-based delivery platform that uses encapsulated, engineered cells as on-site “factories” to secrete cytokines, signaling proteins that regulate immune activity and tissue regeneration, over extended periods. By localizing cytokine production at the wound site, the system is designed to maintain therapeutic levels of these molecules where they are needed most.
The device, developed in the laboratory of Omid Veiseh, encapsulates ARPE-19 cells engineered to secrete specific cytokines, including IL-10, IL-12, and TGF-β. These cells are housed within a biocompatible matrix that allows nutrients and therapeutic proteins to pass through while shielding the cells from the host immune system.
In preclinical studies, the delivery of cytokines using the patch supported accelerated wound healing in both murine and porcine excisional wound models, demonstrating the potential of sustained, localized immunomodulation to enhance natural repair processes.
“The findings show how continuous, localized cytokine delivery can support key biological pathways involved in tissue repair,” said Veiseh, professor of bioengineering at Rice and faculty director of the Rice Biotech Launch Pad. “By maintaining a consistent presence of these signaling molecules at the wound site, we can more effectively engage the body’s natural healing response.”
At the cellular level, the engineered cells demonstrated activation of key wound-healing pathways, which was validated through RNA sequencing. Transcriptomic analysis revealed coordinated upregulation of genes associated with tissue regeneration and immune modulation, providing a mechanistic basis for the functional improvements observed.
The platform is designed to be modular, allowing the engineered cells to be adapted to produce different combinations of cytokines, growth factors, or other therapeutic proteins depending on the clinical application. In addition, the system incorporates an optimized hydrogel matrix that supports integration with the wound environment and may be further adapted to work alongside bioelectronic components.
“The ability to tune both the type and timing of cytokine delivery opens the door to more precise control over the healing process,” said Christian Schreib, assistant research professor in the Department of Bioengineering at Rice and co-author of the paper. “Future work will focus on expanding the flexibility of the platform, including approaches such as optogenetic control to regulate cytokine secretion in real time.”
Beyond wound healing, the cytokine factory approach represents a broader framework for localized, cell-based delivery of therapeutic proteins across a range of diseases where sustained, site-specific signaling is critical.
Funding: The research was supported by the Defense Advanced Research Projects Agency (D20AC00002).
Published in journal: Nature Biomedical Engineering
Authors: Christian C. Schreib, Elizabeth L. Kelley, Gillian Audia, Raghav Garg, Scott Johnson, Samantha Fleury, Marissa N. Behun, Dilrasbonu Vohidova, Mangesh Kulkarni, Grace M. Donnell, Bryan N. Brown, Stephen F. Badylak, Tzahi Cohen-Karni & Omid Veiseh
Source/Credit: Rice University | Silvia Cernea Clark
Edited by: Scientific Frontline
Reference Number: beng052726_01
.jpg)